Compass Therapeutics, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing antibody-based therapies targeting angiogenesis and the tumor immune microenvironment. This report covers the unaudited three months ended March 31, 2023, filed May 4, 2023.
- Clinical-stage programs: CTX-009 and CTX-471.
- CTX-8371 is expected to enter clinical development in the second half of 2023.
- In January 2023, the company redirected internal research from early-stage discovery toward translational research and preclinical development support.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | Not applicable |
| Research and development expense | $6.6 million | $4.4 million | +$2.2 million, or 50% |
| General and administrative expense | $3.1 million | $2.8 million | +$0.3 million, or 11% |
| Total operating expenses | $9.7 million | $7.2 million | +$2.5 million |
| Loss from operations | $(9.7) million | $(7.2) million | $(2.5) million |
| Other income | $1.9 million | $20 thousand | +$1.9 million |
| Net loss | $(7.8) million | $(7.2) million | $(0.7) million |
| Net loss per share | $(0.06) | $(0.07) | Improved per share due primarily to higher share count |
| Cash used in operating activities | $(12.2) million | $(7.9) million | $(4.3) million |
The filing does not provide a meaningful gross or operating margin because the company has no product revenue. Interest income on marketable securities was the principal source of other income.
- Cash and cash equivalents at March 31, 2023: $27.0 million.
- Marketable securities: $148.1 million.
- Total cash, cash equivalents and marketable securities: approximately $175.2 million.
- Total assets: $188.0 million; total liabilities: $12.7 million; stockholders’ equity: $175.3 million.
- Accumulated deficit: $280.7 million.
- The company had no reported debt obligations other than operating lease liabilities. Lease liabilities totaled $2.6 million, including $1.1 million current and $1.5 million long term.
- Management expects existing cash resources to fund operating expenses and capital expenditures into 2026 under current plans.
Material changes versus the prior comparable period
- Research and development expense increased 50%, primarily from higher program-related costs. CTX-009 expense increased to $3.9 million from $0.6 million.
- CTX-471 expense decreased to $0.9 million from $1.3 million, and CTX-8371 expense decreased to $0.5 million from $0.9 million.
- Operating cash burn increased to $12.2 million from $7.9 million.
- Interest income increased substantially to $1.9 million from $20 thousand because of the company’s larger investment portfolio and higher interest rates.
- Cash and marketable securities declined from approximately $186.6 million at December 31, 2022 to approximately $175.2 million at March 31, 2023.
- Accrued expenses declined to $8.9 million from $11.7 million, while accounts payable declined to $1.1 million from $3.4 million.
- Accrued project expenses included approximately $8.1 million of manufacturing expenses for CTX-009, including $6.6 million of minimum contractual obligations.
Guidance, outlook, risks and unusual items
- CTX-009: Two U.S. trials were open, including a Phase 2 colorectal cancer trial and a randomized Phase 2/3 biliary tract cancer trial in combination with paclitaxel. The company is also conducting a Phase 2 biliary tract cancer trial in South Korea.
- CTX-471: A Phase 1 combination trial with Merck’s KEYTRUDA is evaluating patients with advanced cancers that progressed after prior PD-1 or PD-L1 therapy. First interim data were expected in the second half of 2023.
- CTX-8371: IND-enabling studies, including GLP toxicology studies, were completed in the first quarter. The company targeted an FDA IND submission in the third quarter of 2023 and clinical trial initiation in the second half of 2023.
- The company expects expenses to increase substantially as clinical development progresses and expects to require additional funding to complete development, commercialize products if approved, and pursue potential in-licenses or acquisitions.
- Potential future financing through equity or convertible debt could dilute existing stockholders. Debt or other strategic financing could impose restrictive covenants or require the company to relinquish rights to products or technologies.
- Clinical, regulatory, manufacturing and commercialization success remains uncertain. The company has not generated product revenue and may never achieve profitability.
- COVID-19-related supply delays have affected, and may continue to affect, the timing of clinical trials.
- ABL Bio may receive up to $96 million in development and regulatory milestones and up to $303 million in commercial milestones for CTX-009 oncology indications, in addition to royalties. Additional milestone obligations may arise under other collaboration agreements.
- No material legal proceedings, unregistered equity sales, defaults upon senior securities or material changes in internal control were reported.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2023.
Important facts for investors to verify
- Whether the stated cash runway into 2026 remains valid as clinical enrollment, manufacturing obligations and program costs evolve.
- Progress, enrollment and interim data from the CTX-009 and CTX-471 clinical trials.
- Timing and acceptance of the planned CTX-8371 IND submission and clinical start.
- The company’s future financing requirements and potential dilution or strategic licensing consequences.
- CTx-009 manufacturing commitments, including the $6.6 million minimum contractual obligation included in accrued expenses.
- Regulatory, clinical, supply-chain and collaboration risks described in the company’s Form 10-K risk factors.